Table 2.
Outcomes of switching to nilotinib
| Reason for switch to nilotinib | Total N (%) | Responded N (%) | No response N (%) | Stopped due to toxicity N (%) |
|---|---|---|---|---|
| Result of switching | ||||
| Intolerance to imatinib | 4 (10.8%) | 4 (100%) | 0 (0%) | 0 (0%) |
| Loss of CHR | 20 (54.1%) | 14 (70%) | 4 (20%) | 2 (10%) |
| BC | 3 (8%) | 1 (33%) | 2 (66%) | – |
| Not achieved CHR | 2 (5.4%) | 0 (0%) | 2 (100%) | – |
| Loss of CCR/MMR | 2 (5.4%) | 0 (0%) | 1 (50%) | 1 (50%) |
| No achievement of CCR/MMR | 6 (16%) | 1 (17%) | 3 (50%) | 2 (33%) |